SCHEMBL3550870

SCHEMBL3550870

COC(=O)C1(NS(=O)(=O)c2ccc(Cl)c(COc3cccc4c(C)cc(C)nc34)c2Cl)CCOCC1

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BDKRB2 P30411 20/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549506 0.93 BDKRB2 (0.70) BDKRB2
SCHEMBL4062473 0.93 BDKRB2 (0.73) BDKRB2
SCHEMBL13548663 0.88 BDKRB2 (0.77) BDKRB2
SCHEMBL5905821 0.86 BDKRB2 (0.74) BDKRB2
SCHEMBL13548661 0.86 BDKRB2 (0.76) BDKRB2
SCHEMBL3550868 0.85 BDKRB2 (0.61) BDKRB2
SCHEMBL5184373 0.83 BDKRB2 (1.00) BDKRB2
SCHEMBL4057825 0.82 BDKRB2 (0.62) BDKRB2
Fasitibant SCHEMBL29537993 0.81 BDKRB2 (1.00) BDKRB2
Fasitibant SCHEMBL2337275 0.81 BDKRB2 (1.00) BDKRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645759-B2 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-01-12 US disclosed
US-7645759-B2 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2010-01-12 US disclosed
EP-1799214-B1 NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM LUSO FARMACO INST (IT) 2007-12-26 EP disclosed
US-20070281944-A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2007-12-06 US disclosed
US-20070281944-A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281944-A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom BDKRB2, BDKRB1, BRS3 BDKRB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.